When analysing only patients with type II endometrial cancer EGFR expression, but not HER2 gene amplification, was statistically significantly associated with worse OS when compared with those patients with either non-HER2 amplified or non-EGFR expressing EC (HER2, median OS 18 vs 29 months, P=0.113; EGFR, median OS 20 vs 33 months, P=0.028; Figure 3A and B). Here, ERBB2 is linked to endometrial cancer.